Cargando…

Combination of bortezomib and daunorubicin in the induction of apoptosis in T-cell acute lymphoblastic leukemia

Despite advances in the treatment of T-cell acute lymphoblastic leukemia (T-ALL), the outcome of T-ALL treatment remains unsatisfactory, therefore, more effective treatment is urgently required. The present study examined the cytotoxicities of bortezomib in combination with daunorubicin against huma...

Descripción completa

Detalles Bibliográficos
Autores principales:	Du, Xin, Tong, Jia, Lu, Hongying, He, Cong, Du, Shenghong, Jia, Peimin, Zhao, Weili, Xu, Hanzhang, Li, Junmin, Shen, Zhixiang, Wu, Yingli, Tong, Jianhua, Zhou, Li
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2017
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5482122/ https://www.ncbi.nlm.nih.gov/pubmed/28487980 http://dx.doi.org/10.3892/mmr.2017.6554

Ejemplares similares

USP7 deubiquitinates and stabilizes NOTCH1 in T-cell acute lymphoblastic leukemia
por: Shan, Huizhuang, et al.
Publicado: (2018)

Risk Factors of Daunorubicine Induced Early Cardiotoxicity in Childhood Acute Lymphoblastic Leukemia: A Retrospective Study
por: Samosir, Sunny Mariana, et al.
Publicado: (2021)

The induction of apoptosis by daunorubicin and idarubicin in human trisomic and diabetic fibroblasts
por: Dragojew, Sylwia, et al.
Publicado: (2008)

Daunorubicin-60 versus daunorubicin-90 versus idarubicin-12 for induction chemotherapy in acute myeloid leukemia: a retrospective analysis of the Mayo Clinic experience
por: Tefferi, Ayalew, et al.
Publicado: (2022)

WP1130 reveals USP24 as a novel target in T-cell acute lymphoblastic leukemia
por: Luo, Hao, et al.
Publicado: (2019)

Reduced Dose Intensity of Daunorubicin During Remission Induction for Low-Risk Patients With Acute Lymphoblastic Leukemia: A Retrospective Cohort Study of the Chinese Children’s Cancer Group
por: Zhuang, Yong, et al.
Publicado: (2022)

Treatment of refractory/relapsed adult acute lymphoblastic leukemia with bortezomib-based chemotherapy
por: Zhao, Junmei, et al.
Publicado: (2015)

Venetoclax and Bortezomib in Relapsed/Refractory Early T-Cell Precursor Acute Lymphoblastic Leukemia
por: La Starza, Roberta, et al.
Publicado: (2019)

Vorinostat and quinacrine have synergistic effects in T-cell acute lymphoblastic leukemia through reactive oxygen species increase and mitophagy inhibition
por: Jing, Bo, et al.
Publicado: (2018)

Encephalopathy and brain atrophy during induction chemotherapy in acute lymphoblastic leukemia
por: Li, Qiao‐Ru, et al.
Publicado: (2020)

Time dependent response of daunorubicin on cytotoxicity, cell cycle and DNA repair in acute lymphoblastic leukaemia
por: Al-Aamri, Hussain Mubarak, et al.
Publicado: (2019)

Determination of the DNA repair pathways utilised by acute lymphoblastic leukaemia cells following daunorubicin treatment
por: Al-Aamri, Hussain Mubarak, et al.
Publicado: (2019)

Platelet Microparticles Protect Acute Myelogenous Leukemia Cells against Daunorubicin-Induced Apoptosis
por: Cacic, Daniel, et al.
Publicado: (2021)

CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia
por: Lancet, Jeffrey E., et al.
Publicado: (2018)

Apatinib exhibits anti-leukemia activity in preclinical models of acute lymphoblastic leukemia
por: Deng, Manman, et al.
Publicado: (2018)

Early T-Cell Precursor Leukemia Has a Higher Risk of Induction-Related Infection among T-Cell Acute Lymphoblastic Leukemia in Adult
por: Huang, Kangyu, et al.
Publicado: (2020)

Increased lanosterol turnover: a metabolic burden for daunorubicin-resistant leukemia cells
por: Stäubert, Claudia, et al.
Publicado: (2015)

Adipocytes cause leukemia cell resistance to daunorubicin via oxidative stress response
por: Sheng, Xia, et al.
Publicado: (2016)

Self-Assembled Daunorubicin/Epigallocatechin Gallate Nanocomplex for Synergistic Reversal of Chemoresistance in Leukemia
por: Bae, Ki Hyun, et al.
Publicado: (2022)

High Doses of Daunorubicin during Induction Therapy of Newly Diagnosed Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis of Prospective Clinical Trials
por: Gong, Qiang, et al.
Publicado: (2015)

Effects of cytochrome P450 family 3 subfamily A member 5 gene polymorphisms on daunorubicin metabolism and adverse reactions in patients with acute leukemia
por: Huang, Zhen, et al.
Publicado: (2017)

Adipocyte metabolism of the chemotherapy daunorubicin
por: Mittelman, Steven D., et al.
Publicado: (2018)

Marine Benthic Cyanobacteria Contain Apoptosis-Inducing Activity Synergizing with Daunorubicin to Kill Leukemia Cells, but not Cardiomyocytes
por: Oftedal, Linn, et al.
Publicado: (2010)

The efficacy and safety of daunorubicin versus idarubicin combined with cytarabine for induction therapy in acute myeloid leukemia: A meta-analysis of randomized clinical trials
por: Wang, Hanyu, et al.
Publicado: (2020)

Magnetic nanoparticle of Fe(3)O(4) and 5-bromotetrandrin interact synergistically to induce apoptosis by daunorubicin in leukemia cells
por: Chen, Baoan, et al.
Publicado: (2009)

Novel gene signature reveals prognostic model in acute lymphoblastic leukemia
por: Chen, Panpan, et al.
Publicado: (2022)

Downregulating CREBBP inhibits proliferation and cell cycle progression and induces daunorubicin resistance in leukemia cells
por: Gao, Chao, et al.
Publicado: (2020)

Casein-Based Nanoparticles: A Potential Tool for the Delivery of Daunorubicin in Acute Lymphocytic Leukemia
por: Zahariev, Nikolay, et al.
Publicado: (2023)

Anti-CD123 antibody-modified niosomes for targeted delivery of daunorubicin against acute myeloid leukemia
por: Liu, Fu-rong, et al.
Publicado: (2017)

Increased plasma membrane traffic in daunorubicin resistant P388 leukaemic cells. Effect of daunorubicin and verapamil.
por: Sehested, M., et al.
Publicado: (1987)

Adjunction of a fish oil emulsion to cytarabine and daunorubicin induction chemotherapy in high-risk AML
por: Gyan, Emmanuel, et al.
Publicado: (2022)

Cytotoxic Effects of Vitamin A in Combination with Vincristine, Daunorubicin and 6‐Thioguanine upon Cells from Lymphoblastic Leukemic Patients
por: Pieters, Rob, et al.
Publicado: (1991)

Prognostic significance of leukopenia during the induction phase in adult B cell acute lymphoblastic leukemia
por: Xing, Chongyun, et al.
Publicado: (2018)

Prognostic relevance of genetic variations in T-cell acute lymphoblastic leukemia/lymphoblastic lymphoma
por: Yu, Hui, et al.
Publicado: (2019)

Increased Th17 cells and IL-17A exist in patients with B cell acute lymphoblastic leukemia and promote proliferation and resistance to daunorubicin through activation of Akt signaling
por: Bi, Laixi, et al.
Publicado: (2016)

An observational study of Chinese adults with relapsed/refractory Philadelphia-negative acute lymphoblastic leukemia
por: Ma, Jun, et al.
Publicado: (2018)

Liposomal daunorubicin as treatment for Kaposi’s sarcoma
por: Petre, Christin E, et al.
Publicado: (2007)

Interactions of Cisplatin and Daunorubicin at the Chromatin Level
por: Firouzi Niaki, Erfaneh, et al.
Publicado: (2020)

Venetoclax combined with daunorubicin and cytarabine (2 + 6) as induction treatment in adults with newly diagnosed acute myeloid leukemia: a phase 2, multicenter, single-arm trial
por: Suo, Xiaohui, et al.
Publicado: (2023)

Individualized leukemia cell-population profiles in common B-cell acute lymphoblastic leukemia patients
por: Yu, Jian-Hua, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_ftjdg4nbkf5uq4eth7ioadr9od